November 11, 2015—The biopharmaceutical industry’s affinity for orphan drugs keeps growing, with orphans projected to account for 20.2 percent of all prescription drug sales worldwide by 2020 – up from 11.2 percent in 2010 and 6.1 percent in 2000, a new study shows.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)